CYTOKINETICS, INCORPORATED Operating Expenses
CYTOKINETICS, INCORPORATED (CYTK) reported Operating Expenses of $207.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED operating expenses for the quarter ending 2026-06-30 was $207.80M, a 16.56% increase year-over-year.
- CYTOKINETICS, INCORPORATED operating expenses for the quarter ending 2026-03-31 was $202.97M, a 29.11% increase year-over-year.
- CYTOKINETICS, INCORPORATED operating expenses for the quarter ending 2025-12-31 was $196.12M, a 25.75% increase year-over-year.
- CYTOKINETICS, INCORPORATED operating expenses for the quarter ending 2025-09-30 was $168.69M, a 19.42% increase year-over-year.
- CYTOKINETICS, INCORPORATED operating expenses for fiscal 2025 was $700.30M, a 26.24% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED operating expenses for fiscal 2024 was $554.72M, a 10.12% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED operating expenses for fiscal 2023 was $503.74M, a 20.28% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED operating expenses for fiscal 2022 was $418.79M, a 63.12% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $207.80M 10-Q · filed 2026-08-06 | $410.77M 10-Q · filed 2026-08-06 | $606.89M derived: sum of 3 quarters · filed 2026-08-06 | $775.58M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $202.97M 10-Q · filed 2026-05-05 | $399.09M derived: sum of 2 quarters · filed 2026-05-05 | $567.78M derived: sum of 3 quarters · filed 2026-05-05 | $746.06M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $196.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $364.81M derived: sum of 2 quarters · filed 2026-02-26 | $543.09M derived: sum of 3 quarters · filed 2026-08-06 | $700.30M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $168.69M 10-Q · filed 2025-11-05 | $346.97M derived: sum of 2 quarters · filed 2026-08-06 | $504.18M 10-Q · filed 2025-11-05 | $660.14M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $178.28M 10-Q · filed 2026-08-06 | $335.49M 10-Q · filed 2026-08-06 | $491.45M derived: sum of 3 quarters · filed 2026-08-06 | $632.72M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $157.21M 10-Q · filed 2026-05-05 | $313.18M derived: sum of 2 quarters · filed 2026-05-05 | $454.44M derived: sum of 3 quarters · filed 2026-05-05 | $584.86M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $155.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $297.23M derived: sum of 2 quarters · filed 2026-02-26 | $427.65M derived: sum of 3 quarters · filed 2026-02-26 | $554.72M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $141.26M 10-Q · filed 2025-11-05 | $271.69M derived: sum of 2 quarters · filed 2025-11-05 | $398.75M 10-Q · filed 2025-11-05 | $527.85M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $130.42M 10-Q · filed 2025-08-07 | $257.49M 10-Q · filed 2025-08-07 | $386.58M derived: sum of 3 quarters · filed 2026-02-26 | $509.22M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $127.07M 10-Q · filed 2025-05-06 | $256.16M derived: sum of 2 quarters · filed 2026-02-26 | $378.80M derived: sum of 3 quarters · filed 2026-02-26 | $501.72M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $129.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $251.73M derived: sum of 2 quarters · filed 2026-02-26 | $374.65M derived: sum of 3 quarters · filed 2026-02-26 | $503.74M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $122.64M 10-Q · filed 2024-11-07 | $245.56M derived: sum of 2 quarters · filed 2024-11-07 | $374.64M 10-Q · filed 2024-11-07 | $503.63M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $122.92M 10-Q · filed 2024-08-09 | $252.00M 10-Q · filed 2024-08-09 | $380.99M derived: sum of 3 quarters · filed 2025-02-27 | $491.94M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $129.09M 10-Q · filed 2024-05-10 | $258.07M derived: sum of 2 quarters · filed 2025-02-27 | $369.03M derived: sum of 3 quarters · filed 2025-02-27 | $468.87M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $128.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $239.94M derived: sum of 2 quarters · filed 2025-02-27 | $339.79M derived: sum of 3 quarters · filed 2025-02-27 | $418.79M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $110.96M 10-Q · filed 2023-11-03 | $210.80M derived: sum of 2 quarters · filed 2023-11-03 | $289.80M 10-Q · filed 2023-11-03 | $367.11M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $99.84M 10-Q · filed 2023-08-03 | $178.85M 10-Q · filed 2023-08-03 | $256.15M derived: sum of 3 quarters · filed 2024-02-28 | $330.79M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $79.00M 10-Q · filed 2023-05-05 | $156.31M derived: sum of 2 quarters · filed 2024-02-28 | $230.95M derived: sum of 3 quarters · filed 2024-02-28 | $288.59M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $77.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $151.94M derived: sum of 2 quarters · filed 2024-02-28 | $209.58M derived: sum of 3 quarters · filed 2024-02-28 | $256.74M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $74.64M 10-Q · filed 2022-11-04 | $132.28M derived: sum of 2 quarters · filed 2022-11-04 | $179.44M 10-Q · filed 2022-11-04 | $222.57M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $57.64M 10-Q · filed 2022-08-05 | $104.80M 10-Q · filed 2022-08-05 | $147.93M derived: sum of 3 quarters · filed 2023-03-01 | $184.43M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $47.16M 10-Q · filed 2022-05-06 | $90.29M derived: sum of 2 quarters · filed 2023-03-01 | $126.79M derived: sum of 3 quarters · filed 2023-03-01 | $162.74M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $43.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $79.63M derived: sum of 2 quarters · filed 2023-03-01 | $115.58M derived: sum of 3 quarters · filed 2023-03-01 | $149.77M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $36.50M 10-Q · filed 2021-11-05 | $72.45M derived: sum of 2 quarters · filed 2021-11-05 | $106.64M 10-Q · filed 2021-11-05 | $135.56M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | $35.95M 10-Q · filed 2021-08-06 | $70.14M 10-Q · filed 2021-08-06 | $99.06M derived: sum of 3 quarters · filed 2022-02-25 | $129.04M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | $34.19M 10-Q · filed 2021-05-07 | $63.10M derived: sum of 2 quarters · filed 2022-02-25 | $93.09M derived: sum of 3 quarters · filed 2022-02-25 | $126.94M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2019-12-31 | $28.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $58.90M derived: sum of 2 quarters · filed 2022-02-25 | $92.75M derived: sum of 3 quarters · filed 2022-02-25 | $125.73M 10-K · filed 2022-02-25 | ||
| 2019-09-30 | $29.98M 10-Q · filed 2020-11-06 | $63.84M derived: sum of 2 quarters · filed 2020-11-06 | $96.82M 10-Q · filed 2020-11-06 | $127.65M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-06-30 | $33.85M 10-Q · filed 2020-08-07 | $66.83M 10-Q · filed 2020-08-07 | $97.67M derived: sum of 3 quarters · filed 2021-02-26 | $126.22M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-03-31 | $32.98M 10-Q · filed 2020-05-08 | $63.82M derived: sum of 2 quarters · filed 2021-02-26 | $92.37M derived: sum of 3 quarters · filed 2021-02-26 | $122.00M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2018-12-31 | $30.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $59.39M derived: sum of 2 quarters · filed 2021-02-26 | $89.02M derived: sum of 3 quarters · filed 2021-02-26 | $120.42M 10-K · filed 2021-02-26 | ||
| 2018-09-30 | $28.55M 10-Q · filed 2019-11-01 | $58.18M derived: sum of 2 quarters · filed 2019-11-01 | $89.58M 10-Q · filed 2019-11-01 | $126.09M derived: sum of 4 quarters · filed 2019-11-01 | ||
| 2018-06-30 | $29.63M 10-Q · filed 2019-08-09 | $61.03M 10-Q · filed 2019-08-09 | $97.54M derived: sum of 3 quarters · filed 2019-08-09 | $132.14M derived: sum of 4 quarters · filed 2019-08-09 | ||
| 2018-03-31 | $31.40M 10-Q · filed 2019-05-09 | $67.91M derived: sum of 2 quarters · filed 2019-05-09 | $102.51M derived: sum of 3 quarters · filed 2019-05-09 | $130.76M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $36.51M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $71.11M derived: sum of 2 quarters · filed 2019-03-07 | $99.36M derived: sum of 3 quarters · filed 2019-03-07 | $126.76M 10-K · filed 2019-03-07 | ||
| 2017-09-30 | $34.60M 10-Q · filed 2018-11-09 | $62.85M derived: sum of 2 quarters · filed 2018-11-09 | $90.25M 10-Q · filed 2018-11-09 | $115.70M derived: sum of 4 quarters · filed 2018-11-09 | ||
| 2017-06-30 | $28.25M 10-Q · filed 2018-08-07 | $55.65M 10-Q · filed 2018-08-07 | $81.10M derived: sum of 3 quarters · filed 2018-08-07 | $106.18M derived: sum of 4 quarters · filed 2018-08-07 | ||
| 2017-03-31 | $27.40M 10-Q · filed 2018-05-10 | $52.85M derived: sum of 2 quarters · filed 2018-05-10 | $77.94M derived: sum of 3 quarters · filed 2018-05-10 | $94.75M derived: sum of 4 quarters · filed 2018-05-10 | ||
| 2016-12-31 | $25.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $50.53M derived: sum of 2 quarters · filed 2018-03-05 | $67.34M derived: sum of 3 quarters · filed 2018-03-05 | $87.72M 10-K · filed 2018-03-05 | ||
| 2016-09-30 | $25.08M 10-Q · filed 2017-11-03 | $26.56M 10-Q · filed 2016-11-03 | $41.90M derived: sum of 2 quarters · filed 2017-11-03 | $62.27M 10-Q · filed 2017-11-03 | $63.74M 10-Q · filed 2016-11-03 | $81.05M derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-06-30 | $16.81M 10-Q · filed 2017-08-04 | $37.19M 10-Q · filed 2017-08-04 | $55.97M derived: sum of 3 quarters · filed 2018-03-05 | $72.80M derived: sum of 4 quarters · filed 2018-03-05 | ||
| 2016-03-31 | $20.38M 10-Q · filed 2017-05-04 | $39.15M derived: sum of 2 quarters · filed 2018-03-05 | $55.99M derived: sum of 3 quarters · filed 2018-03-05 | $73.12M derived: sum of 4 quarters · filed 2018-03-05 | ||
| 2015-12-31 | $18.78M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-05 | $35.61M derived: sum of 2 quarters · filed 2018-03-05 | $52.74M derived: sum of 3 quarters · filed 2018-03-05 | $66.06M 10-K · filed 2018-03-05 | ||
| 2015-09-30 | $16.83M 10-Q/A · filed 2016-12-15 | $33.96M derived: sum of 2 quarters · filed 2016-12-15 | $47.29M 10-Q/A · filed 2016-12-15 | $60.62M derived: sum of 4 quarters · filed 2017-03-06 | ||
| 2015-06-30 | $17.13M 10-Q · filed 2016-08-04 | $30.45M 10-Q · filed 2016-08-04 | $43.79M derived: sum of 3 quarters · filed 2017-03-06 | $59.20M derived: sum of 4 quarters · filed 2017-03-06 | ||
| 2015-03-31 | $13.32M 10-Q · filed 2016-05-05 | $26.66M derived: sum of 2 quarters · filed 2017-03-06 | $42.07M derived: sum of 3 quarters · filed 2017-03-06 | |||
| 2014-12-31 | $13.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $28.75M derived: sum of 2 quarters · filed 2017-03-06 | $61.69M 10-K · filed 2017-03-06 | |||
| 2014-09-30 | $15.41M 10-Q · filed 2015-11-05 | $48.36M 10-Q · filed 2015-11-05 | ||||
| 2013-12-31 | $64.54M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |